BRAF V600E-mutated marginal zone lymphoma may exhibit partial overlapping lymphocytes.

An international medical study has yielded new findings that have important reference value for disease prevention. The findings have established the frequency of BRAF mutations in borderline region lymphomas (MZL) and investigated their effects on clinical performance, pathological characteristics and disease classification. Traditional pathology, immunopathology, routine cell and molecular biology methods have been used.

We found two MZL cases carrying the BRAF V600E mutation: a BRAF V600E mutation in the ligament MZL (NMZL)) and a non-V600E BRAF mutation in the non-ligament MZL (NMZL)). These NMZL cases exhibit strong CD25 and CD123 expression and patchy cyclin D1 expression characteristics; in addition, there are BRAF V600E mutations that overlap with HCL. However, the remnants of the lymph nodes, as well as the expression of the two key markers for the absence of annexin A1 and CD103, support the accurate classification of MZL as NMZL.

Both cases extend the variation spectrum of MZL and vividly illustrate important and common diagnostic misdiagnosis. These observations emphasize that BRCA2 V600E, although highly specific and of clinical practical value in the context of HCL, still has the potential to have a significant effect on patients in a number of ways. It should be pointed out that the above content is based on international public research findings and is for reference in HealthCop and does not constitute clinical advice.

If you have any health questions, please consult professional medical personnel.